MedMira's HIV/Hepatitis C Rapid Test Selected by Centers for Disease Control and Prevention (CDC) for Collaborative Evaluation Program

MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that the Centers for Disease Control and Prevention (CDC) in the United States has selected the Company's Multiplo HIV/Hepatitis C (HCV) Rapid Test to be a part of a program entitled "Opportunity to Collaborate in the Evaluation of Rapid Diagnostic Tests for HIV and HCV".

This program of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) at the Centers for Disease Control and Prevention (CDC) of the Department of Health and Human Services (DHHS) will see evaluations done in laboratories and in the field to determine the viability of rapid tests for use in screening and/or diagnosis of HIV and HCV in the United States.

A number of rapid tests will be evaluated as part of the program however Multiplo HIV/HCV will be the only combination rapid flow-through test with the ability to deliver simultaneous results for HIV and HCV.

"We are very pleased that our Multiplo HIV/HCV test was selected for evaluation in this important CDC program. International evaluations and feedback from leading researchers have been very positive and we fully expect that our proven technology platform will continue to exceed expectations as part of this program," said Hermes Chan, CEO of MedMira Inc. "In today's economy, where every healthcare budget is being closely scrutinized, a multiple test makes the most sense. Multiplo is essentially a 2-in-1 test that costs the healthcare provider less while delivering results faster than any two single tests combined. It is a win-win for healthcare providers and their patients."

According to the CDC's latest reports, an estimated 1,106,400 people in the United States are living with HIV, with approximately 21% unaware of their status. Approximately 3.2 million persons in the United States have chronic hepatitis C virus infection. About one quarter of HIV-infected persons in the United States are also infected with hepatitis C virus.

Chan continued," It is widely understood that more testing and more people knowing their status significantly decreases the spread of diseases like HIV and Hepatitis C. Multiplo simultaneously diagnoses HIV and Hepatitis C from a single drop of specimen in just three minutes, increasing the number of people who know their status for both HIV and Hepatitis C."

Built on MedMira's award-winning, patented rapid diagnostic technology platform, Multiplo HIV/HCV requires just one drop of whole blood, serum or plasma to detect HIV and/or HCV infections. The 3-step procedure takes three minutes to perform and yields instant results. No sophisticated laboratory equipment or refrigeration is required, making the test ideally suited for a broad range of testing environments, from hospital laboratories, to point-of-care, to mobile outreach clinics and in the future over-the-counter.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00013053E

SOURCE: MEDMIRA INC.

Andrea Young, MedMira, (902) 450-1588, This email address is being protected from spambots. You need JavaScript enabled to view it.